Your browser doesn't support javascript.
loading
Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.
Tamaki, Nobuharu; Ahlholm, Noora; Luukkonen, Panu K; Porthan, Kimmo; Sharpton, Suzanne R; Ajmera, Veeral; Kono, Yuko; Dave, Shravan; Ahmed, Aijaz; Sundaram, Vinay; Wilkinson, Michael J; Patton, Heather; Gupta, Hersh; Cervantes, Vanessa; Hernandez, Christie; Lopez, Scarlett J; Loomba, Ria; Baumgartner, Amanda; Richards, Lisa; Arkkila, Perttu Et; Nemes, Katriina; Isoniemi, Helena; Yki-Järvinen, Hannele; Loomba, Rohit.
Afiliação
  • Tamaki N; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Ahlholm N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Luukkonen PK; Department of Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
  • Porthan K; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
  • Sharpton SR; Department of Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
  • Ajmera V; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
  • Kono Y; Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
  • Dave S; Department of Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
  • Ahmed A; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
  • Sundaram V; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Wilkinson MJ; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Patton H; Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Gupta H; Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Cervantes V; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
  • Hernandez C; Karsh Division of Gastroenterology and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Lopez SJ; Division of Cardiovascular Diseases, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Loomba R; Gastroenterology Section, VA San Diego Healthcare System, San Diego, California, USA.
  • Baumgartner A; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Richards L; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Arkkila PE; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Nemes K; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Isoniemi H; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Yki-Järvinen H; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Loomba R; Nonalcoholic Fatty Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
J Clin Invest ; 132(21)2022 11 01.
Article em En | MEDLINE | ID: mdl-36317632
BACKGROUNDA pilot, single-center study showed that first-degree relatives of probands with nonalcoholic fatty liver disease (NAFLD) cirrhosis have a high risk of advanced fibrosis. We aimed to validate these findings using 2 independent cohorts from the US and Europe.METHODSThis prospective study included probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD, with at least 1 first-degree relative. A total of 396 first-degree relatives - 220 in a derivation cohort and 176 in a validation cohort - were enrolled in the study, and liver fibrosis was evaluated using magnetic resonance elastography and other noninvasive imaging modalities. The primary outcome was prevalence of advanced fibrosis in first-degree relatives.RESULTSPrevalence of advanced fibrosis in first-degree relatives of probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD was 15.6%, 5.9%, and 1.3%, respectively (P = 0.002), in the derivation cohort, and 14.0%, 2.6%, and 1.3%, respectively (P = 0.004), in the validation cohort. In multivariable-adjusted logistic regression models, age of ≥50 years (adjusted OR [aOR]: 2.63, 95% CI 1.0-6.7), male sex (aOR: 3.79, 95% CI 1.6-9.2), diabetes mellitus (aOR: 3.37, 95% CI 1.3-9), and a first-degree relative with NAFLD with advanced fibrosis (aOR: 11.8, 95% CI 2.5-57) were significant predictors of presence of advanced fibrosis (all P < 0.05).CONCLUSIONFirst-degree relatives of probands with NAFLD with advanced fibrosis have significantly increased risk of advanced fibrosis. Routine screening should be done in the first-degree relatives of patients with advanced fibrosis.FUNDINGSupported by NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515, K23DK119460), NHLBI (P01HL147835), and NIAAA (U01AA029019); Academy of Finland grant 309263; the Novo Nordisk, EVO, and Sigrid Jusélius Foundations; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 777377. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the EFPIA.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article